Breakthrough cancer research technologies to advance treatments

Breakthrough cancer research technologies to advance treatments

23 September 2015

Laboratory Signage
A generous gift from the Australian Cancer Research Foundation
has enabled the opening of an Australian-first cancer research facility.

A new partnership between the Australian Cancer Research Foundation (ACRF) and Melbourne’s Walter and Eliza Hall Institute has led to the establishment of an Australian-first facility to research and develop new treatments for cancer.

The $2.5 million ACRF Breakthrough Technologies Laboratory, opened today, will give researchers new insights into how cancer develops, and how it can be more effectively treated. 

The facility is Australia’s first dedicated cancer laboratory to use ‘CRISPR/Cas9’ technology to target and directly manipulate genes in cancer cells. This will be used by researchers from the Walter and Eliza Hall Institute and its Victorian Comprehensive Cancer Centre (VCCC) partners to enhance and accelerate research into many of Australia’s most common, and most deadly, cancers including cancers of the blood (leukaemia, lymphoma), breast, ovary, lung and bowel.

The director of the Walter and Eliza Hall Institute, Professor Doug Hilton, said the ACRF Breakthrough Technologies Laboratory would provide an enormous boost to Australia’s cancer research efforts. “It has become clear that technologies such as CRISPR/Cas9 can accelerate new breakthroughs in understanding cancer and developing new treatments,” he said.

“The generosity of ACRF and its donors has allowed us to equip our research teams with precisely the tools they need to advance their research,” Professor Hilton said.

Mr Tom Dery AO, Chairman of the ACRF Board said the contributions Australian researchers are making to improving the prevention, diagnosis and treatment of cancer were very significant.

“More than 14 million people around the world were diagnosed with cancer last year, including more than 125,000 Australians,” he said.

“We are proud to enable the groundbreaking research conducted at the ACRF Breakthrough Technologies Laboratory. The facility will help to accelerate new treatments for people with cancer in Australia and worldwide,” Mr Dery said.

Professor Jim Bishop, Executive Director of the Victorian Comprehensive Cancer Centre, said the ACRF Breakthrough Technologies Laboratory represented a critical addition to the Victoria’s cancer research capabilities. “The facility provides our researchers with unparalleled access to world-leading technology,” he said. 

“The strength of the VCCC lies in the close ties it fosters between the laboratory-based, clinical and other researchers in its partner organisations. This means that discoveries made in the ACRF Breakthrough Technologies Laboratory will be translated into new treatments for cancer as rapidly in Melbourne as anywhere in the world,” Professor Bishop said.

The VCCC is an alliance of ten successful Victorian organisations committed to cancer care: the Walter and Eliza Hall Institute of Medical Research, Peter MacCallum Cancer Centre, Melbourne Health (including The Royal Melbourne Hospital), The University of Melbourne, The Royal Women’s Hospital, The Royal Children’s Hospital, Western Health, St Vincent’s Hospital Melbourne Austin Health and Murdoch Childrens Research Institute.

 

For further information

Vanessa Solomon
Communications Adviser
Ph: +61 3 9345 2971
Mob: +61 431 766 715
Email: solomon@wehi.edu.au

Super Content: 
Research team in a lab

Want to hear about our latest discoveries? Subscribe to our supporter newsletter, Illuminate

Alignment of crystal structures for Bcl-2 family proteins

Collaborative research has led to a new compound that blocks a protein linked to poor responses to treatment in cancer patients

Researchers using a microscope

Our research into bowel development has suggested a new mechanism for how bowel cancer starts.

Cartoon of fertility goddess

A collaborative research team has identified a new way of protecting female fertility after cancer therapy